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ABSTRACT 
 
Retinoic acid (RA) treatment induces hyperlipidemia in humans and animals. RA 
regulates the expression levels of various genes through the induction, 
repression, or coactivation of nuclear receptors, mediating its effects. RA-induced 
hyperlipidemia has been attributed to the induction of apolipoprotein CIII (gene, 
Apoc3), which inhibits lipoprotein lipase activity (LPL). We have shown that 
vitamin A (VA) status and retinoid treatment regulates hepatic lipogenic gene 
expression, suggesting that the induction of lipogenic genes may also contribute 
to hyperlipidemia. To test the hypothesis that retinoids may not affect Apoc3 
expression, we analyzed the expression levels of Apoc3 mRNA in response to 
retinoid treatments or adenovirus- mediated over-expression of nuclear receptors 
mediating RA responses in primary rat hepatocytes and HL1C rat hepatoma cells 
using real-time PCR. We report that retinoids did not induce Apoc3 mRNA 
expression in these cells. The over-expression of hepatocyte nuclear factor 4 
alpha (HNF4α [alpha]) or chicken ovalbumin upstream promoter transcription 
factor 2 (COUP-TFII) significantly induced or inhibited the Apoc3 mRNA level, 
respectively. Therefore, it is concluded that retinoid treatment could not directly 
induce Apoc3 mRNA levels in rat hepatocytes. Instead, the hepatic expression of 
Apoc3 mRNA may be controlled by the expression levels of HNFα and COUP- 
TFII. Furthermore, the mRNA level of Apoc3 in isolated and cultured hepatocytes 
of Zucker Lean (ZL) and Zucker Fatty (ZF) was not significantly changed. 
However, the Rarb and Srebp-1c mRNA levels, two RA-responsive genes, are 
significantly higher in the liver tissue and isolated hepatocytes from ZF rats than 
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that from ZL rats. Therefore, we conclude that RA-induced hyperlipidemia may 
not be attributed to the direct induction of Apoc3 mRNA level in hepatocytes by 
RA, but at least in part to the RA-mediated induction of lipogenic genes such as 
Srebp1-c.  
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INTRODUCTION 
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The World Health Organization (WHO) estimates that 1 billion individuals 
worldwide are diagnosed as overweight or obese based on mean body mass index. The 
current prevalence of overweight and obesity in the United States is 68%, relative to 
approximately 47% in the 1970s (1). Often times, this increase in body weight is 
associated with an increase in blood triglycerides, defined as hyperlipidemia. This 
condition acts as a severe risk factor for co-morbidities associated with obesity such as 
coronary artery disease (CAD) and diabetes mellitus (DM). The fundamental causes of 
this obesity epidemic can be summarized by the increased availability of calorically 
dense foods and a simultaneous decrease in physical activity. However, the 
pathogenesis of obesity and associated co-morbidities is multi-factorial and the 
environmental changes that have contributed to the increased prevalence of obesity 
must be addressed. Despite the obvious link between nutrition and metabolic diseases, 
the roles of individual micronutrients in the development of obesity and diabetes have 
not been actively investigated. 
 Vitamin A (VA, retinol) and molecules with similar physiological functions 
(retinoids) comprise a group of critical and physiologically active molecules for vision, 
normal embryonic development, immune function, and cellular differentiation (2). 
Accordingly, it has invited therapeutic potentials in dermatology and cancer treatments, 
which have enveloped much of retinoid research historically. Even among the first 
clinical studies (3)(4)(5) on patients treated with isotretinoin (13 cis-RA), alterations in 
lipid metabolism were noted and evoked questions on the VA’s roles in lipid 
metabolism. More recently, retinoids have been proposed to play roles in energy 
homeostasis such as adaptive thermogenesis and adipogenesis (6). This comes as our 
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understanding of ligand- receptor interactions for VA metabolites is cultivated which is 
consistent with clinical observations using VA derivatives therapeutically. With the 
development of structural analogs and antagonists for the activation of nuclear 
receptors mediating retinoid effects, the physiological consequences of VA deficiency 
and toxicity have shifted our understanding of VA’s role in the development of metabolic 
disease.  
Obesity and comorbidities are the physiological consequences of a disruption in 
the regulation of body energy storage, which is associated with profound changes in 
hepatic glucose and lipid metabolism. These changes are often attributed to the 
expression levels of hepatic genes involved in glucose and lipid metabolism. VA status 
and retinoids affect hepatic glucose and fatty acid metabolism directly through the 
regulation of the expression of genes involved or indirectly via controlling insulin 
secretion and action (7)(5). One such change that can contribute to elevated plasma 
triglyceride levels is the induction of Apoc3, which historically has been the culprit of 
RA-induced hyperlipidemia. In our studies, we have observed the significant changes in 
Srebp1-c, a transcription factor that activates fatty acid synthesis, in response to VA 
status. In the current model of RA-induced hyperlipidemia, little consideration has been 
given to the impact this could have on the development of hyperlipidemia in patients 
undergoing VA therapy. We hypothesize that Srebp1-c acts as the major contributor to 
RA-induced hyperlipidemia, based on our original observations (9).  
It is imperative to understand the molecular mechanisms that VA employs to 
regulate hepatic and glucose metabolism, the impact of VA status on the development 
of obesity and diabetes, as well as the physiological effects of retinoids on hormonal 
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action leading to insulin resistance. This understanding may provide a novel therapeutic 
technique for controlling abnormal hepatic glucose and lipid metabolism, and thus 
alleviating diabetic and obese phenotypes. 
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CHAPTER II 
 
LITERATURE REVIEW 
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2.1. Overview of VA 
2.1.1 Vitamin A Structure and Function 
 
VA is a fat-soluble vitamin that exists in multiple isomeric forms and promotes the 
maintenance and formation of various body tissues. The retinoids designation 
collectively refers to a family of molecules structurally similar containing a 20 carbon 
structure with a methyl substituted cyclohexenyl ring (beta-ionone ring) and a tetraene 
side chain containing diverse molecular arrangements that control their functions (10). 
The parent molecule, retinol (ROL), contains a hydroxyl group at carbon-15 and has 
been identified as the least potent form of VA, however, can serve as a precursor to 
more active forms. The oxidized product of retinol, retinal (RAL) contains an aldehyde 
group while the biologically active form of VA; retinoic acid (RA) contains a carboxylic 
acid group. VA can also be esterified for storage with the addition of a fatty acyl group at 
carbon-15 to generate retinyl ester (RE) (10). Carotenoids, the provitamin form of VA, 
usually consist of 40 carbon atoms, conjugated double bonds, and may contain one or 
two cyclic structures at the end of their chain. This lends to their ability to be 
metabolized to form one or two ROL molecules after processing depending on the 
enzymatic system used (10).   
2.1.2 Dietary Sources of VA 
Because retinoids are considered essential micronutrients, meaning they cannot 
be synthesized de novo, the recommended daily intake and sources are important to 
discuss. VA is structurally specific to the type of food products containing it, namely 
animal or plant products. There are a variety of naturally occurring foods rich in VA 
sources. These foods are typical of the Western diet, suggesting that the majority of 
North Americans do meet the dietary recommendations for this micronutrient, potentially 
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in excess. The animal-derived products contain preformed VA in the form of ROL or RE 
and plant products deliver the provitamin form called carotenoids, which can serve as a 
precursor for ROL (10). Dietary provitamin A carotenoids such as β-carotene, α-
carotene, and β-cryptoxanthin can be identified in the pigments of certain yellow, red, 
orange, or purple fruits and vegetables and additionally in red palm oil (10). The animal 
products rich in VA content include liver, milk, cheddar cheese, and egg substitutes. To 
prevent the consequences of a deficiency or toxicity of VA, the RDA for men (900 µg 
ROL activity equivalents (RAE)) and women (700 µg RAE) have been established (10). 
If these recommendations are not met, the consequences can cause systemic 
disruption of various developmental and metabolic processes.  
2.1.3 Uptake of Dietary Retinoids 
 VA’s, in the form of preformed retinoids or provitamin form, initial uptake begins 
in the lumen of the intestine (6). It is apparent that for optimal retinoid absorption, fat 
must be consumed to act as a facilitator for incorporation of retinoids into chylomicrons 
for transport to various tissues (7). To incorporate the retinoid into the chylomicron 
within the enterocyte, ROL can be taken up directly into the lumen for entry into the 
enterocyte while VA in the form of RE must be hydrolyzed first to enter the enterocyte. It 
can be acted upon by a brush-border enzyme hydrolase or a preliminary hydrolase. The 
preliminary hydrolysis is achieved by a retinyl ester hydrolase (REH), named pancreatic 
triglyceride lipase (PTL), an observation made in both rat and human studies (7). PTL is 
also responsible for the hydrolysis of cholesterol esters. Another REH proposed to act in 
synergy with PTL is pancreatic-lipase related protein 2 (PLPR2) working to optimize 
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retinoid absorption by catalyzing the hydrolysis of RE. Following hydrolysis, ROL can 
now be taken up by the enterocyte (7).     
Dietary β-carotene must also be enzymatically cleaved in the enterocyte to 
subsequently be converted back into ROL and then RE. This RE will be incorporated 
into the nascent chylomicron for transport (6). This provitamin form will enter the 
enterocyte with the help of scavenger receptor class B, type 1 or SR-B1. SR-B1 also 
facilitates the transport of cholesterol into the enterocyte (6). The central cleavage of β-
carotene by β-carotene monoxygenase type I (Bcmo1) will result in the creation of one 
to two RAL molecules (7). This aldehyde can then be reduced to ROL by retinal 
reductases, which currently are not well-characterized (6).  
Once in the enterocyte, ROL will be bound to cellular retinol-binding protein II 
(CRBP-II) and then esterified back to RE which is catalyzed by two different enzymes, 
lecithin: retinol acyltransferase (LRAT) and intestinal acyl-CoA: retinol acyltransferase, 
(ARAT) (6, 7). However, approximately 90% of the catalytic activity is attributed to LRAT 
(7). After esterification, RE will be packed with dietary fat and cholesterol into nascent 
chylomicrons for entrance into the lymphatic circulation system. This process is 
illustrated in Figure 2.1 below.  
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Figure 2.1 Schematic of retinoid uptake within the intestine. (11) Abbreviations: 
ApoB: apolipoprotein B, CRBPII: cellular retinoic-acid binding protein II, BCMO1: β-
carotene-15,15’ monooxygenase, DGAT1: diacylglycerol acyltransferase 1, LRAT: 
lecithin: retinol acyltransferase, MTP: microsomal triglyceride transfer protein, PLRP2: 
pancreatic lipase related protein 2, PTL: pancreatic triglyceride lipase, REH: retinyl ester 
hydrolase, SR-B1: scavenger receptor class B, type 1 
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2.1.4 Retinoid Transport in Circulation 
 Because VA in its alcohol form, ROL, has the ability to disrupt membrane 
function, it must be transported through the blood bound to transporters (12). 
Extracellular transport of these retinoids can be in the form RE, incorporated into 
chylomicrons in the lymphatic system as previously described, and/or attached to 
retinol-binding proteins in the bloodstream (RBP) (9). Moreover, ROL can be carried 
through the serum bound to transthyretin, a carrier of thyroxine (T4) and ROL (13), 
which is synthesized by hepatocytes to aid in the transport of VA. Also, the liver is the 
primary site of VA metabolism, which allows the body to meet tissue needs for VA 
through the release into circulation.   
2.1.5 Body Stores 
The liver serves as the principle site of VA storage. In fact, in times of VA 
adequacy, over 90% of stored VA is in the liver as the RE form. It is important to note 
that whole-body VA status can affect the efficiency of hepatic VA storage. Using radio-
isotopic methods, it was found that dietary VA retention can be as high as 50% in times 
of VA homeostasis ; this efficient retention can be compromised in individuals of lower 
VA status (10).    
2.1.6 Hepatic Retinoid Metabolism: VA Storage and Conversion to Active 
Metabolites 
 The liver acts as the primary site of VA storage and postprandial uptake after 
uptake and processing by the small intestine (14)(11). ROL and RE can be delivered to 
the liver via two routes, either associated with lipoproteins via the lymphatic to blood 
circulation system or bound to a RBP in the bloodstream (11). Entrance of bound ROL 
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is achieved by receptor-mediated endocytosis mediated by retinoic acid (RA) gene 6 
(STRA6) (15). In contrast, the RE-rich lipoprotein (chylomicron remnants) will be 
associated with early endosomes and undergo hydrolysis via intracellular hydrolases in 
order to enter the hepatocyte (15). It has been documented that the hydrolysis is 
facilitated by a number of enzymes classified as retinyl ester hydrolases, 
carboxylesterases, and lipases (11).  
 Once hydrolysis is achieved, the ROL has diverse fates (16). It can be transported 
to a specialized cell in the liver known as hepatic stellate cells (HSC) where it will be re-
esterified for storage as RE in the lipid droplets (17). This seems to be a mechanism to 
prevent VA deficiency by increased storage if VA mobilization is needed in times of 
deficiency (11). Once in the HSC, the presence of the enzyme lecithin: retinol acyl:CoA 
transferase (LRAT) will catalyze the esterification of ROL for storage as RE in the lipid 
droplets of the HSC. The other constituents stored in these droplets include 
triglycerides, cholesterol, cholesteryl ester, phospholipids, and free fatty acids (18). 
 In contrast to storage, the ROL available in the liver can be oxidized to RAL and 
consequently the active form of VA, RA. It is generally accepted that this conversion to 
the active form and later effects on gene expression will take place in target cells, 
meaning the liver is not the only site of VA storage but also the site of RA synthesis. 
However, since RA-responsive nuclear receptors have been identified and expressed in 
the liver, the hepatic conversion of ROL to its biologically active form is important to 
discuss. The conversion of ROL to RA is a two-step reaction with the rate- limiting step 
being the oxidation of ROL to RAL. The second step is the irreversible oxidation of RAL 
to the active metabolite RA (2). The enzymes involved in the oxidative steps towards 
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production of RA seem to be tissue-specific and product specific. For example, current 
literature divides the enzymes into three categories: alcohol dehydrogenases, aldehyde 
dehydrogenases, and cytochrome P450s (16). Those enzymes facilitating the reversible 
oxidation/reduction reaction of ROL to RAL are termed dehydrogenases and exhibit 
properties as an alcohol dehydrogenase (ADH) or a short- chain dehydrogenase 
reductase (SDR) (19). For the irreversible oxidation of RAL to RA, enzymes are 
classified in the aldehyde dehydrogenase family (ALDH). This complex network of 
enzymes consists of 17 different isoforms as a whole, all proposed to exhibit essential 
properties to retinoid homeostasis confirmed through knock-out and transgenic rodent 
models (19). This process is illustrated in Figure 2.2 (16). 
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Figure 2.2 Hepatic Retinoid Metabolism. The oxidation of retinol into retinaldehyde 
and retinoic acid and diverse fates of retinol in hepatic processing (16). 
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 Last, another important family of enzymes to consider in retinoid homeostasis is 
the CYP26 enzyme group. Cyp26a1 (cytochrome P450 hydroxylase 26A) is responsible 
for modification of RA molecules to facilitate RA disposal. It serves as the primary 
CYP26 enzyme expressed in the liver, contributing the largest amount of activity in the 
clearance of RA from humans (14)(20). This gene irreversibly oxidizes RA into more 
polar metabolites for excretion. Because Cyp26a1 contains a RA response element 
(RARE) in its promoter region, it is deemed likely that the transcription of the mRNA of 
this enzyme will dynamically reflect the levels of RA in the cell and in turn promote 
oxidation of RA into more polar metabolites (2). 
2.1.7 Activation of Retinoic Acid Receptor (RAR) and Retinoid X Receptor (RXR) 
 
 The biologically active metabolite of VA is RA, which exists in multiple isomeric 
forms. RA isomers activate two families of nuclear receptors: RA receptors (RARα, β, 
and γ; activated by all-trans and 9-cis RA) and retinoid X receptors (RXRα, β, and γ; 
activated by 9-cis RA). RAR/RXR hetero- and RXR/RXR homo-dimers bind to RAREs in 
the promoters of RA responsive genes and regulate their expression upon activation 
(21). Physiological consequences of this activation varies depending on receptor moiety 
and succeeding recruitment of cofactor complexes (22). It has been indicated RXR can 
act as a universal dimerization partner for other families of nuclear receptors including 
peroxisome proliferator activated receptors (PPARs), liver X receptor (LXR), farsenoid X 
receptor (FXR), pregnane X receptor (PXR), thyroid hormone receptor (TR), and vitamin 
D receptor (VDR) (23). This suggests a complex transcriptional network that allows the 
bioactive form of VA, RA, to exert its biological activity.   
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2.2 Vitamin A in Health and Disease 
2.2.1 Consequences of VA Deficiency 
VA deficiency is caused by a lack of VA availability and stores in the human 
body. The WHO states approximately 13.8 million children suffer to varying degrees of 
VA deficiency evidenced by visual losses (24). Signs and symptoms of vitamin A 
deficiency (VAD) include but are not limited to: xerophthalmia, anorexia, compromised 
growth, increased vulnerability to infections, augmented development of hair follicles, 
and keratinization of epithelial cells with associated failure to properly differentiate. VAD 
can be caused by compromising nutrition factors including iron deficiency and chronic 
alcohol consumption. Because ROL and ethanol are metabolized in similar pathways, 
there is the potential for competition for enzymatic breakdown. Not surprisingly, 
individuals with chronic alcohol consumption may be subject to VAD due to 
malabsorption of essential micronutrients and depletion of hepatic VA stores. VAD can 
be corrected through oral supplementation, food fortification, and dietary diversity. In 
order to preserve public health in developing countries, government has sought to fortify 
staple foods of different regions with VA to prevent undesirable consequences of VAD. 
2.2.2 Toxicity: Hypervitaminosis A 
Although VA is an essential micronutrient, a tolerable upper limit (UL) has been 
established in order to prevent adverse physiological effects resulting from excessive 
VA intake. Hypervitaminosis A can be caused by acute or chronic exposure to high 
doses of VA. The severity of the system’s response is dose-dependent and varies with 
molecular arrangements of retinoid structures (25). Acute hypervitaminosis A can occur 
as a result of a single-dose of VA administration and is typically presented with nausea, 
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vomiting, double vision, headache, dizziness, and desquamation of skin (26). However, 
chronic excessive intake (i.e., VA oral supplementation) is manifested by anorexia, 
alopecia, bone and muscle pain, and liver damage—most often associated with VA 
supplementation (26). Excess VA can also be teratogenic, increasing the risk of 
malformations in the fetus, evident in several animal models (27). After the introduction 
of retinoids for treatment of skin disorders in humans, a rise in spontaneous abortions 
and birth defects was observed in women ingesting 13-cis-RA (isotretinoin, Accutane®) 
and etretinate (Tegison, Tigason). As a result, these drugs became contraindicated 
during pregnancy (27). Additionally, toxic effects on the liver may include hyperplasia of 
the stellate cells, hypertrophy, fibrogenesis, sclerosis of veins, portal hypertension, and 
congestion of perisinusoid cells, which can accelerate the development of cirrhosis (26).   
2.2.3 Role of VA in Cellular Differentiation 
VA, specifically the biologically active RA, is necessary for normal cell 
differentiation for specific cell types. For labile cells, VA will induce cell differentiation 
and inhibit the cell-division cycle. Epithelium depends on VA for maintenance of 
homeostatic function and structure(28). Consequently, VA isomers have been widely 
utilized topically and systemically for skin disorders. RA functions to activate gene 
transcription for the synthesis of keratin proteins (12), a key component of skin and hair. 
Moreover, it has been reported that hormones and their signaling cascades can 
regulate mesenchymal stem cells differentiation characteristics for osteoblasts and 
adipocytes. Recently, RA has been shown to inhibit adipocyte differentiation and 
stimulate osteoblastogenesis, affecting the balance of this process (29).  
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2.3 Roles of VA in Energy Metabolism 
2.3.1 VA Affects Hepatic Glucose Metabolism 
 For glucose utilization in hepatocytes, it is first phosphorylated into glucose-6- 
phosphate by hexokinase D, glucokinase (GK). Insulin induces the hepatic expression 
levels of GK gene (Gck) in the liver. It has been shown that all-trans ROL, RAL, and RA 
are able to synergize with insulin to induce Gck expression via the activation of 
RAR/RXR in primary rat hepatocytes (30). Furthermore, the Gck expression level is 
reduced in the VAD rats in comparison to the VA sufficient (VAS) controls. RA treatment 
rapidly recovered this reduction (30). 
The liver generates glucose via gluconeogenesis in response to nutritional and 
hormonal stimuli. The first rate limiting enzyme for hepatic gluconeogenesis is the 
cytosolic form of phosphoenolpyruvate carboxykinase (PEPCK-C), whose activity is 
controlled by the expression of its gene (Pck1) (31). Insulin suppresses the hepatic 
expression of Pck1 (32). It has been shown that RA stimulates the Pck1 expression in 
hepatoma cells via two RARE in its promoter (33). To understand the effects of the 
endogenous lipophilic molecules on the expression of insulin-regulated hepatic genes, 
lipophilic extracts were prepared from rat livers. The lipophilic extracts (LE) induced 
Pck1 expression levels and attenuated insulin-mediated reduction of its expression in 
primary rat hepatocytes (34). Subsequently, the active molecules in the extract were 
identified as ROL and RAL, and the proximal RARE in the Pck1 promoter was found to 
be responsible for arbitrating retinoids effects in primary rat hepatocytes (8)(30). An 
increase in the hepatic VA content has been observed in diabetic patients (35) as well 
as streptozotocin-induced diabetic rats (36) which may contribute to the alterations in 
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insulin-regulated gene expression. Because the primary function of ROL and RE is to 
serve as precursors for biosynthesis of RA, it is important to investigate the 
physiological consequence of this increase in VA storage. The retinoids effects on the 
hepatic expression of Pck1 (8) and Gck (30) demonstrate the interaction between the 
insulin and retinoid signaling pathways, which deserves further investigation. 
2.3.2 Impact of whole-body VA status and retinoid availability on hepatic FA 
metabolism 
 The liver plays a critical role in the maintenance of hepatic lipid homeostasis, 
relying on a delicate balance of lipid uptake, synthesis, catabolism, and excretion. 
Alterations in lipogenesis, fat oxidation, and lipoprotein metabolism can favor the 
development of obesity and the metabolic syndrome (37). Several transcription factors 
cooperate in the control of hepatic lipogenesis including liver X receptor (LXR) and 
sterol regulatory element–binding protein 1c (SREBP-1c), a transcription factor that 
induces the expression of hepatic lipogenic genes (38) . The expression of its gene 
(Srebp-1c) is induced by insulin, or activations of LXR and RXR (39). The insulin-
responsive elements of Srebp-1c promoter have been identified as two LXR receptor 
elements (LXRE) and one sterol regulatory element (SRE) in its promoter (40). Later, it 
was shown that RA was capable of inducing Srebp1-c in primary rat hepatocytes and 
the LXREs are also RAREs (9).  
 A significant portion of patients with acne receiving isotretinoin (13-cis RA) 
treatment developed hypertriglyceridemia (41). In addition, clinical studies have 
indicated that the excessive VA supplementation resulted in hepatic hypervitaminosis A, 
which exacerbates abnormal lipid storage in the liver (42). Rats fed multiple isomeric 
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forms of RA all displayed hypertriglyceridemia, consistent with human observations (3). 
Rats on a VAD diet exhibited a lowered plasma lipid profile compared to VAS controls 
(43). This may be caused by the dual existence of VA deficiency and hypoinsulinemia, 
which results in the reduction of hepatic lipogenesis (44). The activation of RXR by its 
specific agonist (LG100268) induced hepatic lipogenesis, which interestingly increased 
insulin sensitivity in obese and diabetic rats (45). Since Srebp1-c is a critical 
transcription factor for lipid homeostasis (46) and RA has been shown to affect the 
insulin-mediated expression of Srebp-1-c (9), it is reasonable to conclude that VA status 
and retinoids play roles in hepatic FA homeostasis. 
2.3.3 VA Status in Animals and Retinoids Affect Insulin Secretion from Pancreatic 
β-cells  
 
 Insulin controls hepatic glucose and fatty acid metabolism in response to 
macronutrients. Glucose metabolism causes the rise of ATP/ADP ratios and 
subsequently stimulates the release of insulin from insulin granules in pancreatic β-cells 
(47). Glucose stimulated insulin secretion (GSIS) is impaired in VAD rats and is 
recovered by VA repletion (44). Additionally, VAD rats had pancreatic β-cell dysfunction 
which may be attributed to a reduction in fetal β-cell mass (7) . In isolated rat pancreatic 
islets, ROL either potentiated (0.1µmol/L) or inhibited (100 µmol/L) GSIS (48). RA was 
capable of potentiating GSIS via induction of transglutaminase activity in INS-1 cells 
(49). Recently, it has been shown that pancreatic β-cells produce 9-cis RA, whose level 
is elevated in islets of diet-induced obesity, ob/ob and db/db mice (50). When mouse 
islets were treated with 9-cis RA, GSIS was reduced due to a reduction in GLUT2 and 
GK activities (50). In addition, lipid depletion in pancreatic β-cells caused impairment of 
GSIS, which can be restored in the presence of FAs (51). Additionally, RA has been 
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reported to induce Srebp-1c mRNA in INS-1 insulin secreting cells (9). Taken together, 
VA status or retinoid levels can indirectly control hepatic glucose and FA metabolism 
through regulating the insulin secretion from pancreatic β-cells. If RA is produced in the 
islets, it becomes essential to learn the mechanism for the production of the various RA 
isoforms to fully understand the roles of the retinoids in pancreatic β-cell function.  
2.4 Impact of Vitamin A Derivatives on Lipid Metabolism 
2.4.1 Pharmacological Uses of VA and Contraindications 
 Lipid alterations have been contraindicated for the use of VA derivatives as 
pharmacologic agents. Attributed to their role in cellular differentiation, VA derivatives 
have been universally used in the treatment of hyper- and parakeratotic skin disease, 
severe acne, and some lymphomas for the past three decades (52). In fact, isotretinoin 
(13-cis retinoic acid, or [Accutane]) is the treatment of choice for severe acne that is 
non-responsive to other forms of treatment. It has been reported that in 70-80% of 
patients, long-term remission from severe acne is achieved with this medication (53). 
Unfortunately, in approximately 20% of these patients, there is an observed elevation of 
TG-rich lipoproteins that, depending on the severity, may cause acute pancreatitis. Lipid 
disturbances after administration of systemic therapy with VA derivatives have provoked 
dermatologists to monitor fasting plasma lipid levels routinely after treatment. These 
alterations in lipid metabolism can vary depending on the specific ligand-receptor 
interactions that occur. The table below identifies the receptor-binding classes of 
commonly used VA derivatives.  
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Table 2.1 Classification and profiles of VA derivatives for systemic administration 
(52) 
 
Chemical 
Components 
 
Substance 
 
Receptor 
Endogenous 
Metabolite/Synthetic 
Indication 
All-trans RA Tretinoin RAR Metabolite Acute 
promyelocytic 
leukemia; Acne 
Vulgaris; 
Kerotosis 
Polaris 
13-cis RA Isotretinoin RAR Metabolite Cystic Acne 
Vulgaris 
13-cis-RA Acitretin RAR Synthetic Psoriasis, 
lichen planus 
9-cis-RA Bexarotene RXR Synthetic Cutaneous T-
cell lymphoma 
9-cis-RA Alitretinoin RAR/RXR Metabolite Chronic hand 
dermatitis; 
Kaposi’s 
sarcoma 
 
 For some of these pharmacological agents, they are exclusively used to treat skin 
disorders when other therapeutic alternatives unavailable. For example, alitretinoin 
serves as the only licensed systemic treatment for chronic hand dermatitis. It becomes 
important to maximize its therapeutic potential by eliminating contraindications such as 
the undesirable effects on lipid metabolism.  
2.4.2 Proposed Mechanisms of Lipid Disturbances During VA Therapy 
 The mechanism that VA derivatives employ to cause rapid disturbances in lipid 
metabolism remains elusive. Currently, it is believed this change in lipid metabolism is 
due to RAR activation resulting in a marked, reversible, dose-dependent elevation in 
serum lipids and VLDL particles (54). The mechanism proposed is increased production 
of TG-rich VLDL through inhibition of fatty acid degradation in the liver. This inhibition 
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causes accelerated hepatic TG production and decreased clearance of VLDL particles 
by LPL. Additionally, hepatic Apo C-III is increased due to RXR activation (55).  Human 
ApoC-III is a major factor in determining plasma triglyceride levels. Elevated Apo C-III 
results decreased uptake of TG-rich lipoproteins from the blood, causing hyperlipidemia 
(4)(54).  
Beyond this, there seems to be a genetic predisposition to develop pathologic 
serum lipid levels during VA therapy (56). Previous diagnoses for various chronic 
diseases such as obesity, DM, hypothyroidism, CHD, previous MI and kidney 
dysfunction are contraindications to VA therapy as they place the patient at risk for 
adverse changes in lipid profile. Furthermore, it has been proposed that VA therapy 
may reveal latent, familial hyperlipidemia disorders which characteristically lie quiescent 
during childhood and gradually apparent as an individual ages (57) (5).  
2.4.3 Insulin-Mediated Apoc3 Transcriptional Regulation 
It has been reported that insulin-dependent diabetes mellitus (IDDM) patients 
who exhibit non-compliance to insulin therapy have elevated plasma TG levels that can 
be normalized upon insulin treatment (58)(59)(60). These elevated TG levels have been 
linked to a state of insulin deficiency where LPL activity is decreased resulting in 
decreased TG clearance from VLDL and chylomicrons in the blood. This is possible in 
accordance with the human observation of increased ApoCIII activity in the insulin-
deficient state, contributing to hyperlipidemia. Concomitantly, insulin’s inability to inhibit 
hormone-sensitive lipase (HSL) in adipose tissue causes an influx of FFA to the liver, 
inducing VLDL synthesis. The combined effects of these metabolic changes have been 
shown to contribute to increased triglyceride levels. Indeed, STZ-treated diabetic mice 
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showed a decrease in Apoc3 mRNA in response to insulin treatment. This is reasonable 
due to the presence of an insulin-response element (IRE) in the Apoc3 gene promoter 
(61). Therefore, it becomes important to understand the contributions of both Srebp1-c 
and Apoc3 in RA-induced hyperlipidemia.  
2.5 Nuclear Receptors  
The regulation of hepatic glucose and lipid homeostasis is attributed, at least in 
part, to the regulation of the expression levels of genes involved in response to 
hormonal and nutritional stimuli. A transcriptional network that can be impacted by lipid-
soluble factors such as VA orchestrates the liver’s response to nutritional and hormonal 
signals (62). The impacts may be in concert with the expression profiles of those 
transcription factors mediating the hepatocytes differentiation and functions. 
2.5.1 Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUPTF-II) 
COUPTF-II nuclear receptors comprise the most highly conserved subfamilies 
studied. Because of its DNA-binding ability, it can activate or inhibit gene expression 
depending on the presence of certain ligands, corepressors, or coactivators (63). For 
example, COUPTF-II can positively regulate Cyp7a1 expression by recruiting 
coactivators, i.e., glucocorticoid receptors (GR) that further activate gene transcription. 
In contrast, COUPTF-II acts as to repress gene transcription by the recruitment of 
nuclear corepressors to silence activities of other NR such as thyroid receptors (64). 
Targeted deletion of COUPTF-II can be lethal and compromise processes such as 
angiogenesis and cardiovascular development (63). In multiple cell lines, COUPTF-II 
acts constitutively but its activity can be modulated by the presence of ligands such as 
RA (65). Both variants are able to regulate gene transcription because of their ability to 
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bind 5’-AGGTCA-3’ direct repeats (DR) and modulate gene transcription. It has been 
reported that COUPTF-II can activate Rarb (63). Furthermore, RA has been shown to 
release COUPTF-II from the auto-repressed conformation due to its interaction with the 
LBD, which may affect some of the metabolic activities orchestrated by COUPTF-II (66).  
2.5.2 Hepatocyte nuclear factor 4 alpha (HNF4α) 
HNF4α is a liver-enriched transcription factor responsible for regulation of genes 
controlling lipid and bile synthesis, gluconeogenesis, and a variety of liver-specific 
functions (67). It remains one of the most significantly conserved DNA-binding proteins 
in the liver, with an estimated 40% of transcribed genes containing an HNF4α-response 
element (68). Additionally, it has been indicated to direct approximately 11% of genes 
actively transcribed in pancreatic islets (69). Its expression is present in lower amounts 
in tissues such as the kidneys, intestine, and pancreas relative to the liver (70). The 
obligatory role it plays in hepatic lipid homeostasis is implied by the development of 
hepatic steatosis in HNF4α-deficient mouse livers, attributed to the accumulation of liver 
cholesterol (67). Inherited mutations in the human HNF4α gene results in maturity onset 
diabetes of the young type 1 (MODY1), which is characterized by pancreatic β-cell 
dysfunction evidenced by a loss of insulin secretion in response to glucose (71) . 
Moreover, HNF4α maintains the differentiation state, phenotype, as well as directs 
energy metabolism in the hepatocyte (71).  
It has been suggested that the metabolic syndrome and/or diabetes may 
contribute to deleterious effects on liver function characteristic of hepatocellular 
carcinoma which may be arbitrated by a disruption in HNF4α activity (67). Not 
surprisingly, excess energy intake is a factor contributing to non-alcoholic fatty-liver 
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disease (NAFLD), which is characterized by disturbed fat distribution associated with 
significant energy accumulation. The direct results include exacerbating conditions such 
as obesity and insulin resistance, creating a dangerous platform for the development of 
hepatocellular carcinoma (HCC), one of the most prevalent liver cancers in the United 
States and China. While much of the nutritional contributions to these conditions have 
been focused on macronutrient intake, our lab considers the effects of micronutrients as 
a nutritional signal that can impact this transcriptional network. This knowledge may 
impact our understanding of pathophysiological outcomes associated with metabolic 
disorders and invite new target therapies for improving prognosis.  
In humans treated with VA derivatives, 1 in 10 may develop hyperlipidemia as a 
result of these medications.  As mentioned previously, this has been attributed to the 
elevation of Apoc3 mRNA and ApoCIII protein expression. However, little regard has 
been given to the impact of Srebp1-c in the pathogenesis of RA-induced hyperlipidemia. 
It has been indicated that VAD rats had lower plasma TG level and hepatic lipogenic 
activity than VAS rats did (43), suggesting an association between dietary VA intake 
and changes in hepatic lipogenesis. Because Srebp1-c is a critical factor mediating 
hepatic lipogenesis, we want to investigate the contributions of this gene to RA-induced 
hyperlipidemia as well as the mechanism for changes in Apoc3 expression in response 
to retinoid treatment. We have identified two RAREs in the Srebp1-c promoter (9) which 
may be responsible for sensing VA status. Additionally, we have demonstrated that RAL 
and RA have the ability to synergize with insulin to induce Srebp1-c expression in 
primary rat hepatocytes (9).  
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CHAPTER III 
MATERIALS AND METHODS 
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3.1 MATERIALS AND METHODS 
3.1.1 Reagents  
Reagents for primary hepatocyte isolation and culture have been published 
previously (34) as well as the source of LG268 (30). All other compounds ((E)-4-[2-
(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1 -propenyl] benzoic acid or 
TTNBP CAS 71441-28-6, T1317 (N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-
1-(trifluoromethyl)ethyl]phenyl]benzenesulfonamide)) were purchased from Sigma-
Aldrich (St. Louis, MO) unless otherwise noted. Reagents for cDNA synthesis and real-
time PCR were obtained from Applied Biosystems unless otherwise indicated (Foster 
City, CA). Medium 199 (catalog number 11150-059), liver perfusion medium (catalog 
number 17701-038) and liver digest buffer (catalog number 17703-034) were obtained 
from Invitrogen (Life Technologies, Grand Island, NY). Dulbecco's Modification of Eagle 
Medium (DMEM), fetal bovine serum (FBS), and streptomycin/penicillin (catalog number 
091670249) were obtained from Fisher Scientific (Pittsburgh, PA, 15275). Trypsin-
EDTA solution was obtained from Gibco® (catalog number 15050-065, Grand Island, 
NY14072). Primary antibodies against HNF4α, COUP-TFII, and β-actin (#3113, #6434, 
#4970, respectively) were purchased from Cell Signaling Technology, Danvers, MA. 
3.1.2 Animals and Primary Hepatocyte Isolation 
Male Sprague-Dawley (SD) rats were purchased from Harlan Breeders 
(Indianapolis, IN). Male Zucker lean (ZL) and Zucker fatty (ZF) rats were bred at UTK. 
The animals were housed in colony cages, fed a standard rodent diet and 
maintained on a 12-h light/ 12-h dark cycle. The Institutional Animal Care and Use 
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Committee at the University of Tennessee at Knoxville approved all procedures under 
protocol 1642 and 1582.  
For primary hepatocyte isolation, rats were euthanized with carbon dioxide. After 
death, the abdominal cavity was opened by excision. A 24 G catheter was inserted into 
portal vein and connected to a peristaltic pump for infusing liver perfusion medium. 
The inferior vena cava was cut open to allow the outflow of the media at flow rate of 10 
ml/min. Following perfusion (~200ml), the liver was digested with 140 ml of liver digest 
buffer at 10 ml/min. Then, livers were excised from the rat and placed into a tissue 
culture plate containing 30 ml of liver digest buffer to remove connection tissues and 
allow the release of hepatocytes. Medium containing hepatocytes were filtered (100-
microne pores, BD) and spun at 50×g for 3 minutes. The cell pellets were washed twice 
with 50 ml of wash medium: DMEM containing 5% FBS, 100-units/ml sodium penicillin, 
and 100 µg/ml streptomycin sulfate.  After the final wash, cells were suspended in the 
wash medium and the viability of the isolated hepatocytes were determined by Tryptan 
blue staining. The isolated hepatocytes were plated onto collagen type I-coated 60-mm 
dishes (2 to 3 million cells/dish) and incubated in 4 ml of the same medium at 37°C and 
5% CO2. After 3–4 hours, the attached cells were washed once with 4 ml of PBS, and 
incubated in medium 199 supplemented with 100 nM dexamethasone, 100 nM 3,3′,5-
triiodo-l-thyronine (T3), 100 units/ml penicillin, and 100 µg/ml streptomycin sulfate plus 
1 nM insulin for 14–16 hours until being used for the indicated experiments. 
3.1.3 Cell Culture  
HL1c cells, which were stably transfected with a reporter gene construct 
containing a fragment of rat Pck1 promoter (72), were a kind gift from Dr. Donald K. 
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Scott at University of Pittsburgh. Cells were incubated in DMEM supplemented with 4.5 
g/L glucose, 4% FBS, 100 U/mL of penicillin, and 100 µg/mL of streptomycin sulfate at 
37°C and 5% CO2/95% air.  Cells in 60 mm culture dishes were grown to 60-70% 
confluence before being treated with 2 ml serum-free DMEM containing indicated 
reagents in the figure legends for the indicated time as shown in the figure legends. All 
cells were maintained at 37°C and 5% CO2.   
3.1.4 Preparation of Recombinant Adenovirus 
 Methods for recombinant adenovirus generation have been described previously 
(73).  HEK293 cells were seeded into-6-well plates at a density of 1 × 106 cells/well in 
DMEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml 
streptomycin sulfate, and allow to grow to 90% confluence. The cells were co-
transfected with 1 μg each of pACCMV5-rHNF4α and pJM17 with Lipofectamine 2000 
(Life Technologies) according to manufacturer’s instructions. Transfected 293 cells were 
incubated in 2 ml of DMEM containing 2% FBS at 37°C and 5% CO2. Samples 
demonstrating lysis 6-10 days post-transfection were harvested for viral amplification. 
Crude lysates were screened for the presence of the specific genes via PCR. 
 For each recombinant adenovirus, confirmed original crude lysate was then used 
to infect HEK 293 cells grown to 80% confluence in 150 mm tissue culture plates. The 
ratio of the medium to crude lysate is 10 to 1 (v/v). After the lysis of the cells at around 
48 h post infection, the cell culture medium (crude lysate) was collected, and stored at -
80°C until being used. 
 For purification of each recombinant adenovirus, NP-40 was first added into the 
crude lysate to reach the final concentration at 0.5%. The mixture was shaken gently at 
	  	  
30	  
room temperature (RT) for 30 min and subjected to centrifugation at 8,000 rpm and 4°C 
for 15 min. The supernatant was transferred to a clean bottle, and 0.5 × volume of 20% 
PEG8000/ 2.5 NaCl was added. The preparation was shaken gently at 4°C overnight. 
The resulting mixture was transferred to centrifuge bottles and spun at 12,000 rpm at 
4°C for 15 min. The precipitated pellet was resuspended in a small volume of PBS (2-3 
ml), and spun at 12,000 rpm and 4°C for 10 min to remove insoluble matters. Solid CsCl 
was added to the supernatant until its final density reached 1.34 g/ml. The mixture was 
spun at 90,000 rpm at 25°C for 3 h using OptimaTM MAX-XP Ultracentrifuge (Beckman 
Coulter Inc., Brea, CA). The corresponding band containing pure viral particles was 
collected in a total volume less than 1 ml for desalting. The PD-10 column SephadexTM 
G-25 M (Amersham Pharmacia Biotech AB, Sweden) was equilibrated with 5 ml PBS. 
The purified virus in CsCl solution was loaded onto the column and eluted with 5 ml 
PBS. The flow through was collected into ten fractions. The optical density (OD) of each 
of these fractions at 260/nm was determined after 1 to 50 dilution in water using 
Spectronic® GENESYSTM 5 Spectrophotometer (Thermo Scientific Inc., Pittsburgh, 
PA). The fractions containing significant values of OD were collected and pooled. 
Bovine serum albumin (BSA) and glycerol were added to the pooled solution to make 
the stock viral solution with the final concentrations of them at 0.2% and 10%, 
respectively. After the filtration of the stock solution for sterilization, its OD was 
determined to estimate the plaque forming units (pfu) assuming 1 OD equals 1 × 1012 
pfu/ml. The final purified virus stock was frozen at -80°C until being used in the 
indicated experiments. Recombinant adenovirus expressing human COUP-TFII (Ad-
COUP-TFII) was provided by Mireille Vasseur-Cognet (74).  
	  	  
31	  
3.1.5 RNA Extraction and genomic DNA removal 
One milliliter of RNA STAT 60 was added directly to each 60 mm dish containing 
cells treated with indicated reagents. The plate with the reagent was allowed to shake at 
RT for at least 10 minutes. The lysate was transferred to a 1.5 ml micro centrifuge tube. 
Then, the samples were stored at room temperature for 5 minutes, at which time 0.2 ml 
of chloroform was added to each sample. After tightly sealing, the sample was shaken 
vigorously for 15 seconds and left at room temperature for 2 minutes. The samples 
were then centrifuged at 13,000 rpm for 30 minutes at 4°C, resulting in two phases, 
including lower DNA/protein containing red phenol chloroform phase and colorless 
aqueous upper phase containing RNA. The aqueous phase (about 0.5 ml) was 
transferred to a fresh tube and mixed with 0.5 ml of isopropanol. Samples were spun 
immediately at 13,000×g for 20 minutes at 4°C. The precipitated total RNA formed a 
white pellet at the bottom of the tube. The supernatant was removed and RNA pellet 
was washed with 1 ml per tube of 70% ethanol in diethylpyrocarbonate (DEPC) water. 
The sample was vortexed and spun at 7,500xg for 5 minutes at 4° C. RNA was air-dried 
briefly without complete drying in order to preserve solubility. The pellet in each tube 
was dissolved in 0.88 ml of DEPC water and kept at room temperature for 30 minutes.  
For the removal of contaminated genomic DNA in RNA samples, the Ambion® 
DNA-free™ DNase Treatment & Removal Reagents were used. Each RNA sample was 
treated with 4 units of rDNase 1 at 37°C for 30 minutes in a final volume of 100 µL 
containing 100 mM Tris, 25 mM MgCl2, and 5 mM CaCl2 at pH 7.5. Following 
incubation, 10 µL of resuspended DNase Inactivation reagent was added, mixed well 
with samples, and incubated at room temperature for 2 minutes. Samples were 
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centrifuged at 10,000×g for 2 minutes and the supernatant (RNA) was transferred to a 
fresh tube and stored at -80°C until further use.  
3.1.6 cDNA synthesis and real-time polymerase chain reaction (PCR) 
For RNA quantification, 2 µl of each sample was diluted in 998 µl of H2O for the 
measurement of OD at 260 nm using a spectrophotometer (Thermo Scientific 
Spectronic Genesys 5 UV Spectrophotometer model no: 336001). In brief, the 1 mL 
diluents were placed in 1 ml spectrophotometer cuvette and OD was determined at 260 
nm. For cDNA synthesis, 2 µg of DNA-free total RNA was used in a final volume of 100 
µl reaction containing 50 mM Tris-HCl (pH 8.3), 75 mM KC1, 3 mM MgCl2, 20 mM DTT, 
2 mM dNTP, 50 units RNase inhibitor (Life Technology, Ca #: N8080119), and 2.5 µM 
random hexamers (N6). The mixture was incubated at 25°C for 10 minutes, 48°C for 30 
minutes, and 95°C for 5 minutes. First strand cDNA samples were stored at -20°C until 
further use for real-time PCR analysis. Each real-time PCR reaction in a final volume of 
14 µl includes cDNA from 14 ng of reverse transcribed total RNA, 2.33 pmol primers set 
for the indicated gene, and 7 µl of 2 × SYBR Green PCR Master Mix. Triplicate PCR 
reaction was carried out for each cDNA samples in 96-well plates using the ABI 7300 
Real-Time PCR System. The conditions are 50 °C for 2 min, 95 °C for 10 min, followed 
by 40 cycles of 95°C for 15 s and 60 °C for 1 min. The relative amounts of all mRNAs 
were calculated using the comparative CT method with 36B4 as the invariant control. 
The real-time primer sets for Cyp6a1(75), Srebp1-c (9), Pepck (30), Rarb , Apoc3 and 
Hnf4α have been previously reported. The oligo nucleotide sequences of real-time PCR 
primer sets are summarized in Table 3.1. The primer set for Coup-tfii (forward- 5’-
	  	  
33	  
TGCCTGTGGTCTGTCTGATG-3’ and reverse- 5’-GGAAGGGAGACGAAGCAAAA-3’ ) 
was designed using Primer Express Software (Applied Biosystems).   
3.1.7 Immunoblotting and Protein Band Quantification 
After indicated treatments in the figure legends, HL1c cells in 60 mm dishes were 
washed once with 3 ml PBS and scrapped from the dish into 400 µl of whole-cell lysis 
buffer (1% Triton X-100, 10% glycerol, 1% IGEPAL CA-630, 50 mM Hepes, 100 mM 
NaF, 10 mM EDTA, 1 mM sodium molybdate, 1 mM sodium β-glycerophosphate, 5 mM 
sodium orthovanadate, 1.9 mg/ml aprotinin, 5 µg/ml leupeptin, 1 mM benzamide, 2.5 
mM PMSF, pH 8.0). The lysates were placed on ice for at least 20 min before they were 
subjected to centrifugation at 13,000 rpm for 20 min. The protein concentration in the 
supernatant was determined with PIERCE BCA protein assay kit (Rockford, IL). This 
was achieved by first mixing 50 parts of Reagent A to 1 part Reagent B to make working 
reagent (WR), provided by assay kit. 25 µL of each standard and each unknown sample 
was then pipetted into appropriately labeled tubes. 200 µL of the WR was then added to 
each sample and mixed well. The tubes were then covered and incubated at 37°C for 
30 minutes. All tubes were then cooled to room temperature.  
For the standard curve, protein concentration was measured using a plate reader 
set at 562 nm. The average absorbance of the blank standard replicates at 562 nm was 
then subtracted from the 562 nm measurements of all other individual standard and 
unknown sample replicates. A standard curve was prepared by plotting the average 
blank-corrected 562 nm measurement for each BSA standard vs. its concentration in 
µg/mL. The standard curve with a formula was then created and used to determine the 
protein concentration of each unknown sample.   
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To make the resolving gel, 2 mL 30:0.8% w/v acrylamide:bisacrylamide,  3 mL 
1.0M Tris-Cl pH 8.8, 38 µL 20% SDS, and 2.43 mL dH20 were mixed together and 36 
µL of 10% APS and 5 µL of TEMED to reach a final volume of 7.5 ml. To make the 
stacking gel 660 µL of 30:0.8% w/v acrylamide:bisacrylamide, 30 µL 1.0M Tris-Cl pH 
6.8, 25 µL of 20% SDS and 3.6m mL of dH20 were mixed. After mixing, 25 µL 10% APS 
and 5 µL TEMED was added immediately before pouring for a total of 5 mL. Proteins 
(40 µg/lane) in whole cell lysates were separated on an 8% SDS-PAGE gel.  It was then 
transferred (1.5 hr) to BIO-RAD Immuno-Blot PVDF membrane (Hercules, CA), and 
blocked for 1 hr at RT in TBS plus 0.05% TWEEN® 20 (TBST), 5% non-fat dry milk, and 
incubated overnight at 4°C in primary antibodies against HNF4α, COUP-TFII, and β-
actin diluted 1:1000 in TBST and 1% BSA, according to the protocols provided by the 
manufacturers. After this, blots were washed with TBST twice for 5 minutes and twice 
for 10 min. at RT and incubated at RT for 1 hr using a 1:2,000 dilution of goat anti-rabbit 
IgG (#7074P2, Cell Signaling Technology) conjugated to horseradish peroxidase. 
Bound primary antibodies were visualized by chemiluminescence (ECL Western 
Blotting Substrate, Thermo Scientific) and membranes were exposed to X-ray films 
(Phenix Research Products, Candler, NC) for protein band detection. The films were 
scanned using an HP Scanjet 3970 (Palo Alto, CA 94304) and stored as Tagged Image 
File Format (TIFF) at 300 dpi.  
3.1.8 Statistical Analysis 
Cumulative data is presented as means ± standard errors (S.D.). Levene's test 
was used to determined homogeneity of variance among groups using SPSS 21.0 
statistical software (IBM, Armonk, NY) and where necessary natural log transformation 
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was performed before analysis. Multiple comparisons were analyzed by one-way 
analysis of variance (ANOVA) using least significant different (LSD) when equal 
variance was assumed, and Games-Howell test was used when equal variance was not 
assumed. The independent sample t-test was used to compare two conditions. 
Differences were considered statistically significant at P < 0.05. 
Table 3.1 Primer sequences used for qPCR 
Gene  Primer 
(oGC-) 
Sequence (5’-3’) 
36B4  TTCCCACTGGCTGAAAAGGT 
CGCAGCCGCAAATGC 
Rarβ 582 GGCCTCTGGGACAAATTCAG 
GCAGACGCTTGGCGAACT 
583 
Apoc3 1081 GAACAAGCCTCCAAGACGGT 
GGGATTTGAAGCGATTGTCC 
1082 
Hnf4α 998 CAAGAACACATGGGCACCAATG 
GGTGATGGCTGTGGAGTCT 
999 
Cyp7a1 334 GCTTTACAGAGTGCTGGCCAA 
CTGTCTAGTACCGGCAGGTCATT 
335 
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Table 3.1 Continued 
 
Gene  Primer 
(oGC-) 
Sequence (5’-3’) 
Cyp26a1 452 AGTGATGGGCGCGGATAAT 
TGCACTGACACCAACCGGT 
453 
Srebp1-c  GGAGCCATGGATTGCACATT 
AGGCCAGGGAAGTCACTGTCT 
 
Coupt-
fii/Nr2f2 
1057 TGCCTGTGGTCTGTCTGATG 
GGAAGGGAGACGAAGCAAAA 
1058 
Hmgcr 638 CGACATCATCATCCTCACGATAA 
GCTGACGCAGGTTCTGCAA 
639 
Rxrg 658 TGCGGATAAGCAGCTCTTCA 
TCCAAGGTGAGGTCTGAGAAGTG 659 
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CHAPTER IV 
RESULTS AND DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
38	  
4.1 RESULTS AND DISCUSSION 
4.1.1 Elevated Srebp1-c in ZF rats hepatic tissue and isolated hepatocytes may 
contribute to RA-induced hyperlipidemia 
ZF rats (76) have been universally accepted as model systems to study the 
obesity development due to hyperphagia and its effects on related metabolic disorders 
due to an autosomal Mendelian recessive trait affecting all leptin receptor isoforms 
(77)(78). We used this model to analyze the mRNA levels of genes involved in hepatic 
lipid metabolism in isolated primary hepatocytes from ZF and ZL rats in comparison to 
liver tissue. It has been reported that VAD rats display decreased plasma TG levels and 
hepatic lipogenic activity than VAS rats (43). This observation may be a result of 
reduced Srebp1-c activity, a critical gene for fatty acid biosynthesis (46). We have 
shown that retinoids are capable of synergizing with insulin to induce Srebp1-c 
expression via LXR binding sites (9). Consistent with this hypothesis, in both the liver 
tissue and isolated hepatocytes of ZF rats, Srebp1-c mRNA amounts were significantly 
higher than ZL counterparts, as shown in Figure 4.1. This is expected as hepatic lipid 
accumulation and de novo lipogenesis is increased in obese rats while SREBP-1c acts 
as a central transcriptional regulator of these alterations in hepatic lipid metabolism (79). 
Consistent with our overall hypothesis that excessive RA activation contributes to 
obesity, Rarb mRNA, a RA-responsive gene (80), was significantly higher in ZF rats in 
liver tissue and isolated hepatocytes. If we consider the current model of RA-induced 
hyperlipidemia (5), we would expect Apoc3 mRNA to be induced in both liver tissue and 
isolated hepatocytes from ZF rats due to the activity of RA-signaling indicated by Rarb 
induction. In liver tissue from both ZL and ZF rats, Apoc3 mRNA was not significantly 
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different. Interestingly, Apoc3 expression in isolated hepatocytes from ZF was 
significantly higher than that from ZL rats. We believe this is a result of the development 
of insulin resistance, which has been documented in ZF rats (81). It also suggests that 
other cells in the liver probably also contributed to the Apoc3 gene expression. Obese 
ZF rats become hyperinsulinemic and exhibit significant hepatic and peripheral insulin 
resistance (81). Therefore, it is reasonable to conclude that ZF isolated hepatocytes are 
no longer responsive to insulin-mediated suppression of Apoc3 and express 
significantly different levels compared with livers from ZL rats. Similar differences were 
observed in Cyp7a1 expression, whereas, ZF liver tissue exhibited higher amounts of 
Cyp7a1 mRNA, which may again be the result of a change in insulin-mediated 
transcriptional activity. The mRNA levels of various transcription factors, including 
Hnf4a, Rxrg, Hmgcr, and Couptf-ii, were not significantly different among groups in 
hepatocytes or liver tissue. We conclude from this data that the elevated expression of 
Srebp1-c in the liver of ZF rats may be a major contributor of RA-induced 
hyperlipidemia.   
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Figure 4.1 Comparison of mRNA levels in liver tissue and isolated hepatocytes of 
ZL and ZF male rats. Liver tissue and primary hepatocytes were obtained and isolated 
from ZL and ZF rats fed ad libitum. The total RNA was extracted and subjected to real-
time PCR analysis. Results are presented as means ± SD of –ΔCt (against 36B4) from 
the indicated numbers (in parenthesis) of liver samples or hepatocyte isolations for ZL 
and ZF rats (*all P<0.05, for comparing the –ΔCt values of the indicated transcripts in 
liver or hepatocytes from ZL rats with those from ZF rats using independent-samples t 
test). Abbreviations: Hnf4α-hepatocyte nuclear factor 4 alpha, Srebp1-c-sterol 
regulatory element binding protein 1-c, Rarb-retinoic acid receptor beta, Apoc3-
apolipoprotein C-III, Cyp7a1-cytochrome P450 7a1, Rxrg-retinoic acid receptor gamma, 
Nr2f2-nuclear receptor subfamily 2, group F, Hmgcr- 3-hydroxy-3-methylglutaryl-
coenzyme A.  
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4.1.2 RAL treatment induced Rarb, but not Apoc3, mRNA in primary rat 
hepatocytes 
It has been reported that RA treatment directly induces the Apoc3 mRNA levels 
probably via activation of RXRs in HepG2 hepatoma cells and human primary 
hepatocytes derived from healthy organ donors (82). We have identified RAL as one of 
the active lipophilic molecules from our original study that is capable of synergizing with 
insulin to induce Pck1 expression (34)(8). Since we have shown that RA can be 
dynamically synthesized from RAL in primary rat hepatocytes to induce the expression 
of genes involved in glucose and lipid metabolism (2), primary rat hepatocytes were 
treated with increasing concentrations of RAL in the absence or presence of 1 nM 
insulin to determine  Rarb, Hnf4a, and Apoc3 mRNA levels in response to retinoid 
treatment. In the absence of insulin, Rarb mRNA, as a positive gene for retinoid 
treatment, was induced by RAL at 0.2 µM in a dose-dependent manner. Insulin 
treatment inhibited the basal, but not RAL-induced Rarb mRNA expression. Hnf4a 
mRNA level was not affected by RAL and insulin treatments, except for the RAL at 0.02 
µM, which induced Hnf4a expression. The expression level of Apoc3 mRNA was not 
affected by RAL or insulin treatment.  
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Figure 4.2. Effects of RAL on the mRNA levels of Rarb (A), Apoc3 (B), and Hnf4a 
(C) in primary rat hepatocytes. Hepatocytes were incubated in medium A with or 
without increasing concentrations of RAL in the absence or presence of 1 nM insulin for 
6 h. Total RNA was extracted and subject to real-time PCR analysis. The mRNA level of 
the respective gene in ethanol vehicle control group was assigned a value of 1 (mean ± 
SD, n = 3, * P<0.05 for comparing the group in the absence of insulin with the groups in 
the presence of insulin at the indicated RAL dosage). 
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4.1.3 Endogenous Apoc3 expression is not significantly affected in response to 
retinoid treatment in rat hepatoma cells.  
Since retinoids also regulate gene expression in HL1C rat hepatoma cells (3), 
endogenous responses of Apoc3 to retinoids as analyzed. HL1c cells were treated with 
increasing dosages of ROL and RAL and the changes of Rarb, Pck1 and Apoc3 mRNA 
levels were determined. RA has been shown to bind Rarb, mediating its cellular 
signaling. Therefore, we used Rarb and Pck1, known target genes of RA-signaling, as a 
reflection of retinoid activity in this cell. There was a dose-dependent, significant 
increase of Rarb and Pck1 mRNA expression levels in response to RAL treatment 
compared to the vehicle control (Figure 4.3). Additionally, Rarb mRNA levels were 
significantly lower in cells treated with ROL than those with RAL. This is expected as 
ROL has been shown to be less potent than RAL on gene expression because of its 
required metabolism to more active forms (73). For ROL at 2 µM, Pck1 mRNA was 
significantly lower than RAL groups at the same concentration. However, Apoc3 mRNA 
presented no significant changes among all groups, regardless of retinoid potency and 
concentration. Therefore, we concluded that retinoids do not directly affect endogenous 
Apoc3 transcription in rat HL1C hepatoma cells.  
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Figure 4.3. The mRNA expression levels of Rarb, Pck1, and ApoC3 in response to 
retinoid treatment in rat hepatoma cells. HL1c cells were treated with ROL and RAL 
at indicated conditions for gene expression studies. Cells were harvested 6 hours after 
treatment and total RNA was isolated and subjected to reverse transcription to generate 
cDNA. Rarb, Pck1, and ApoC3 expression was detected using RT-PCR relative to an 
internal control gene, 36B4. Results are presented as a means of ± SD of three 
independent experiments. (All P<0.05; a<b, c<d<e using one-way ANOVA; * for 
comparing ROL with RAL groups using independent sample t-test) 
 
 
 
 
 
 
	  	  
47	  
 
 
 
 
	  	  
48	  
4.1.4 Specific agonists activating RAR and RXR are not sufficient to induce Apoc3 
mRNA in rat hepatoma cells. 
RA regulates gene expression through activation of transcription factors, namely 
RXRs and RARs (83). Activation of RAR antagonized the induction of Srebp-1c 
mediated by RXR activation in primary rat hepatocytes (6). Additionally, it has been 
shown that HNF4a directly binds to human Apoc3 promoter sequences (7) and 
mediates glucose-induced Apoc3 expression in primary rat hepatocytes (8). 
Subsequently, we measured the expression levels of Cyp26a1, Pck1, Hnf4a and Apoc3 
mRNA in those cells. It has been reported that pharmacological activation of LXR can 
elevate VLDL synthesis (84). Furthermore, we have shown that RA is capable of 
inducing Srebp1-c expression via LXREs in its promoter to induce hepatic lipogenic 
activities (9). LXRs have been shown to dimerize with RA-specific nuclear receptors to 
direct the actions of lipid metabolism within the cell including lipoproteins (85).  In order 
to understand the roles of these nuclear receptors in VLDL synthesis coupled with RA-
induced hyperlipidemia, ApoC3 mRNA was measured along with reported target genes 
of RA-specific receptors such as Pck1 and Cyp26a1 (73). To determine if activation of 
RAR, RXR or LXR alone plays a role in the regulation of Apoc3 in rat hepatoma cells, 
were treated with TTNBP (1 μM), a specific panagonist of RARs; LG268 (1 μM,), an 
RXR-specific agonist; and T1317 (1 µM), a synthetic agonist for LXR activation in the 
absence or presence of insulin. 
  TTNPB, a potent RAR agonist, significantly induced Cyp26a1 expression, an RA-
responsive gene (75) up to 150-fold in the presence and absence of insulin (1nM) 
(Figure 4.4A). Activation of RXR by LG268 caused a modest induction of Cyp26a1 in 
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the presence or absence of insulin, while LXR activation by T1317 caused suppression 
of Cyp26a1 in comparison to RXR/RAR activation. This suggests that RAR can be 
activated in HL1C cells in the presence of a specific agonist.  
RAR activation can induce Pck1 expression and attenuate insulin-mediated 
suppression of its expression in primary rat hepatocytes (8). Similarly, a robust induction 
of Pck1 expression is observed upon RAR activation with concomitant attenuation of 
insulin-mediated suppression in Figure 4.4B. RXR activation alone did not significantly 
induce Pck1 and insulin-mediated suppression of its expression was not affected, in 
comparison to control. Although RAR activation was sufficient to induce Cyp26a1 and 
Pck1, no significant changes resulted in Hnf4a or Apoc3 mRNA in response to RAR, 
RXR or LXR activation in the presence or absence of insulin (Figure 4.4C and 4.4D). 
Interestingly, Apoc3 mRNA expression was significantly lower in the vehicle control 
group treated with insulin which is consistent with previous reports of insulin’s regulation 
on Apoc3 mRNA expression in diabetic mice (61). However, this reduction was not 
observed in primary hepatocytes (Figure 4.2). Insulin’s ability to suppress Apoc3 gene 
transcription was ablated when RAR, RXR, and LXR activation occurred, as shown in 
Figure 4.4D. These results indicate that activation of these three nuclear receptors in 
HL1c cells is not sufficient to induce Apoc3 mRNA. The observation of RA-induced 
transcription factor’s ability to attenuate insulin-mediated suppression of Apoc3 may 
contribute to increased plasma triglyceride levels. However, the major contribution to 
increased lipogenesis in response to retinoids must be employed by another gene, such 
as Srebp1-c, which deserves further investigation.  
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Figure 4.4 The expression levels of Cyp26a1 (A), Pck1 (B), Hnf4a (C), and Apoc3 
(D) in HL1c cells treated with RAR, RXR, and LXR agonists. HL1c cells were treated 
with vehicle, TTNBP (1μM), LG268 (1μM), and T1317 (1μM) in the absence and 
presence of insulin (1nM) for 6 h. The expression level of the vehicle control group was 
arbitrarily assigned a value of 1. Results are presented as a means of ± SD of three 
independent experiments. (All P<0.05; a<c<b, a’<c’<b’, d<e, d’<e’ using one-way 
ANOVA; # lower compared to the control group without insulin; * comparing two groups 
in the indicated treatments) 
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4.1.5 The over-expression of HNF4α or COUP-TFII respectively induced or 
inhibited the Apoc3 mRNA level in rat hepatoma cells.  
HNF4α constitutes a family of transcription factors that direct the expression of 
several genes in lipid metabolism including the apolipoprotein promoters, thus making it 
capable of influencing plasma triglyceride levels (86). It is possible that RA acts in 
concert to induce or inhibit a coactivator in the regulation of transcriptional activity for 
genes involved in hepatic lipid metabolism, such as Apoc3. The current model of RA-
induced hyperlipidemia considers the induction of Apoc3 expression as the major 
contributor to elevated plasma triglyceride levels. The hormone-response elements 
(HREs) of the ApoC-III promoter can be bound by members of the orphan nuclear 
receptor family as well as ligand-dependent nuclear receptors (86). Because Apoc3 is a 
classical target gene of HNF4α, molecules that can change the binding activity of 
HNF4α may be an indirect result of a change in the activity of the transcription factors 
involved in Apoc3 gene expression. Additionally, COUPT-TFII-ARP-1 serves as one of 
the most evolutionarily conserved orphan nuclear receptors among all species and 
plays a role in various biological processes including metabolic homeostasis (66). Much 
like HNF4α, COUP-TFII seems to be constitutively active and may be transactivated by 
the presence of various coactivators or corepressors (66). For example, it has been 
reported that RXR and COUPTF-II compete antagonistically in vivo for binding to DR-1 
such that COUPTF-II has the ability to completely repress RXR-induced transcription 
activation in various cell lines (87). Because these along with RA-inducible transcription 
factors play a key role in directing the liver’s metabolic activities it becomes important to 
understand their regulation of ApoC3, a major contributor to plasma triglyceride levels. 
	  	  
52	  
We hypothesized that retinoids do not directly influence Apoc3 expression in rat 
hepatoma cells and primary rat hepatocytes. Rather, a change in Apoc3 expression is a 
result of altered HNF4α and COUPTF-II levels in rat hepatoma cells and hepatocytes. 
It is reasonable to propose this idea as the activity of these transcription factors have 
been reported to cause a change in the presence of ligand-activated receptors such as 
RXR in rat hepatocytes.  
As shown in Figure 4.5, the mRNA and protein levels of HNF4α and COUPTF-II 
were dramatically induced when HL1C cells were infected with the recombinant 
adenoviruses.  The mRNA levels of Hnf4a and COUP-TFII expression were induced by 
~153 and ~24 fold, respectively. This is associated with a dramatic elevation of their 
corresponding proteins detected in the whole cell lysates (Figure 4.6A-C). The viral 
dosage that we used was successful to induce over-expression of HNF4α (Figure 
4.6D).  
Figure 7A shows the expression of Apoc3 mRNA in HL1C cells treated with no 
virus, Ad-β-gal or Ad-HNF4α virus in the absence or presence of RAL. The over-
expression of HNF4α significantly induced Apoc3 mRNA (~2-fold higher) compared to 
the control.  The over-expression of Ad-COUPTF-II significantly repressed ApoC3 
expression (~50%), characteristic of its ability to act as a repressor of other transcription 
factors (88). The addition of RAL (1µM) did not affect on Apoc3 gene expression. 
Retinoids induce Pck1 in primary rat hepatocytes (8). In order to show that RAL 
was effective in the cells, basal Pck1 mRNA expression level was significantly reduced 
and increased by over-expression of HNF4α and COUP-TFII, respectively (Figure 
4.7B). RAL treatment significantly induced the Pck1 (~5-fold).  These data indicate that 
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RA derived from RAL treatment can induce the expression of Pck1, a RA responsive 
gene, but not Apoc3 expression in HL1C cells. We conclude from these data that 
retinoids do not directly induce Apoc3 mRNA in short term. The hyperlipidemia in 
patients treated with RA derivatives may be, in part, caused by the induction of Srebp1-
c, which acts to increase hepatic lipogenesis, and contributes to the elevated plasma 
triglyceride levels.  
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Figure 4.5. The adenovirus-mediated overexpression of Ad-HNF4α and Ad-
COUPTF-II in rat hepatoma cells. HL1C cells were maintained in DMEM containing 
4.5-g/L glucose, 4% FBS, 100 U/ml of penicillin and 100 U/ml streptomycin sulfate and 
incubated in 60 mm dishes. HL1c cells were infected at 1,000 pfu/cell for 18 hours with 
indicated Ad-β-gal, Ad-HNF4α, and Ad-COUPTF-II. Cells were then harvested, total 
RNA isolated, and subjected to RT-PCR analysis. The mRNA level of each transcript in 
the cells infected with Ad-β-gal and the vehicle control was arbitrarily assigned a value 
of 1.  
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Figure 4.6. Immuno-blot of adenovirus-mediated overexpression of nuclear 
receptors in rat hepatoma cells.   
 
HL1c cells were infected with Ad-β-gal, Ad-HNF4α, or Ad-COUPTF-II at 100 PFU/cell 
for 18 h. Western blot of proteins (40µg/lane) in whole cell lysates showing relative 
nuclear receptors and β-actin as the loading control.  
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Figure 4.7 The expression levels of HNF4α and COUPTF-II in rat hepatoma cells 
regulate Apoc3 and Pck1 gene expression.  HL1C cells were maintained in DMEM 
containing 4.5-g/L glucose, 4% FBS, 100 U/ml of penicillin and 100 µg/ml streptomycin 
sulfate and incubated in 60 mm dishes. Cells were infected 18 hours before treatment 
with indicated adenovirus, then treated with serum-free medium for 2 hours containing 
vehicle control or RAL at 1 µM. Cells were then harvested, total RNA isolated, and 
subjected to RT-PCR analysis. All P<0.05; b>a>c, b’>a’>c’, g>e>f, e’<f” using one-way 
ANOVA  
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4.2 Summary and Future Directions 
RA-induced hyperlipidemia has historically been attributed to the increase of 
Apoc3 mRNA in hepatocytes, which leads to elevation of plasma TG levels due to the 
inhibitory effect of ApoC3 on LPL. This mechanism has been used to explain studies on 
individuals treated with synthetic VA analogs whose therapy was contraindicated by the 
development of severe secondary hyperlipidemia, which puts them at risk for 
cardiovascular accident. Although this has been a generally accepted belief, the 
emerging role of retinoids in obesity development and energy homeostasis has 
prompted us to gain more insight into the mechanism of RA-induced hyperlipidemia.  
 In our current study, we observed the elevation of Srebp1-c and Rarb mRNA in 
ZF rats, which is consistent with our previous observation of RA-mediated induction of 
hepatic lipogenic activities (73). Excessive activation of Srebp1-c has been associated 
with hypertriglyceridemia (89) and RA with insulin to induces Srebp1-c (9). In our 
current study, the higher expression of Rarb in ZF compared to ZL suggests RA may be 
mediating the induction of Srebp1-c, and thus contributing to increased hepatic 
lipogenesis. Although actively produced in these cells, we could not observe the 
induction of Apoc3 mRNA in liver tissues.  The induction of Apoc3 in isolated 
hepatocytes leads us to believe that insulin resistance in ZF rats compromised insulin-
mediated suppression of this gene (61). It also suggests that other cells may be 
involved in regulating Apoc3 expression.  
Our current study was designed to investigate the effects of RA on the 
expression of Apoc3 mRNA in primary hepatocytes and hepatoma cells.  We observed 
that the mRNA levels of Apoc3 could not be directly induced by retinoid treatment in rat 
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hepatoma cells or primary rat hepatocytes, suggesting this observation is not limited to 
cell lines. Instead, the presence of transcription factors such as HNF4α and COUPTF-II 
could induce or inhibit Apoc3 transcription, respectively in rat hepatoma cells. RA can 
dynamically regulate metabolic activities by interacting with various transcription factors 
to direct changes in gene expression. More specifically, nuclear receptors mediating 
RA-response such as RAR/RXR might participate in the hyperlipidemic effect during VA 
therapy. RAR, RXR, or LXR activation via synthetic analogs was not sufficient to induce 
Apoc3 mRNA in HL1c cells. Interestingly,1nM of insulin was able to suppress Apoc3 by 
as much as 30% and this suppression was attenuated by RAR, RXR, and LXR 
activation. This might be caused by the variations of Apoc3 mRNA levels in the samples 
treated with the ligands of these three nuclear receptors or by the reorganization of 
transcription machinery in response to those ligands. Further studies are needed to find 
out the underlying mechanisms. 
Taken together, we conclude that the expression levels of HNF4a and COUP-
TFII in hepatoma cells can positively and negatively regulate Apoc3 mRNA levels, 
respectively. However, the dynamic production of RA from the RAL could not affect 
Apoc3 expression in the same cells. Since we only measured the acute and direct 
effects of retinoids on Apoc3 gene expression, we could not exclude the possibility that 
RA indirectly regulates Apoc3 mRNA levels via a dynamic change in the activity of 
transcription factors present such as HNF4a and COUPTF-II, rather than a direct 
induction. In Hep3B cells, the RAREs in the promoter of HNF4α genes mediate the 
reduction of Hnf4a mRNA (90) and HNF4α protein levels after the RA treatment for 3 
days (91). The ligand-binding of COUP-TFII is in an autorepressed conformation. At 
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high concentrations, RAs are able to promote COUP-TFII to recruit coactivators and 
activate a COUP-TF reporter construct (66). It seems that further studies are needed to 
reveal the precise mechanism. Based on previously published data and ones presented 
here, it is sufficient to conclude that RA-induced hyperlipidemia may be, at least in part, 
attributed to the elevation of Srebp-1c expression. 
Our overall hypothesis that excessive RA synthesis and activation contributes to 
obesity and associated co-morbidities such as hyperlipidemia is evident in the data 
presented here. By furthering our understanding of RA-induced hyperlipidemia, it may 
provide a novel target therapy for combating obesity and metabolic disorders.  
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